1,349,274 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Sio Capital Management LLC

Sio Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,349,274 shares of the company’s stock, valued at approximately $24,314,000. Teva Pharmaceutical Industries comprises approximately 9.6% of Sio Capital Management LLC’s portfolio, making the stock its 2nd biggest position. Sio Capital Management LLC owned approximately 0.12% of Teva Pharmaceutical Industries as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of TEVA. UMB Bank n.a. raised its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $48,000. Smithfield Trust Co increased its holdings in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Byrne Asset Management LLC bought a new position in Teva Pharmaceutical Industries in the second quarter worth approximately $52,000. Finally, Claro Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of TEVA stock opened at $16.57 on Friday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The business has a 50-day simple moving average of $17.57 and a 200-day simple moving average of $17.35.

Wall Street Analyst Weigh In

TEVA has been the topic of several analyst reports. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.